Hatteras Venture Partners announced today the final closing of Hatteras Venture Partners V (HVP V) with over $150 million in total capital. Hatteras will continue its strategy of building great companies in the human medicine life sciences by investing at the seed and early stage. Like HVP IV, the firm will allocate a portion of HVP V to Hatteras Discovery to expand its successful model of company formation.